Zoledronic acid 5 mg/100 mL bottle; solution for IV infusion. Paget’s disease of bone is characterized by greatly increased and disorderly bone remodeling. Excessive osteoclastic bone resorption is ...

Medicare covers the injectable drug, Reclast, when a doctor deems it medically necessary for the treatment and prevention of osteoporosis. There are specific eligibility criteria, including having ...

Reclast (zoledronic acid) is a medication that the Food and Drug Administration (FDA) has approved for preventing and treating osteoporosis in females after menopause, males, and individuals who take ...

Learn about osteoporosis, its risks, symptoms, and prevention strategies to maintain bone health and prevent fractures.

On Dec 19, 2025, the US Food and Drug Administration (FDA) announced a major milestone by qualifying total hip bone mineral density (BMD), assessed by dual-energy X-ray absorptiometry, as a surrogate ...

WASHINGTON (Reuters) - Swiss drugmaker Novartis A said Friday it had won U.S. approval to sell the first once-a-year treatment for the bone-thinning disease osteoporosis. Sign up here. The drug, ...

Zoledronic acid is effective for reducing hip fracture risk among postmenopausal women with osteoporosis. Zoledronic acid is effective for reducing hip fracture risk among postmenopausal women with ...